ACHV News and Press, Achieve Life Sciences Inc. From 10/17/25

2025-10-17 07:12:04 ET More on Regeneron, Achieve Life Sciences, etc. Regeneron: Growth Catalysts Incoming Achieve Life Sciences: Promising Pipeline But High Risks Makes Me Hold For Now Regeneron: Strong R&D Pipeline Drives Growth Outlook Regeneron gets F...

SEATTLE and VANCOUVER, British Columbia, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline for treatment of nicotine dependence for smoking cessation,...

2025-09-30 10:39:54 ET Achieve Life Sciences, Inc. (NASDAQ: ACHV ), a late-stage specialty pharmaceutical company recently announced some positive news pertaining its sole product candidate for nicotine dependency. The company announced the publication of new data demonstrating ...

SEATTLE and VANCOUVER, British Columbia, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as treatment of nicotine dependence, today announced the p...

2025-09-18 11:46:15 ET More on Achieve Life Sciences Achieve Life Sciences, Inc. (ACHV) Q2 2025 Earnings Call Transcript Achieve Life Sciences: Nearing Commercialization Of A Best-In-Class Pharmaceutical Product For Smoking Cessation Achieve Life Sciences gets new in...

SEATTLE and VANCOUVER, British Columbia, Sept. 18, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline for treatment of nicotine dependence for smoking cessation...

2025-09-12 02:57:01 ET Read the full article on Seeking Alpha For further details see: Achieve Life Sciences gets new interim chief medical officer

SEATTLE and VANCOUVER, British Columbia, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline for treatment of nicotine dependence for smoking cessation...

2025-09-03 10:00:01 ET More on Achieve Life Sciences Achieve Life Sciences, Inc. (ACHV) Q2 2025 Earnings Call Transcript Achieve Life Sciences: Nearing Commercialization Of A Best-In-Class Pharmaceutical Product For Smoking Cessation Achieve Life Sciences Q2 2025 Ear...

Filing based on pivotal Phase 3 ORCA-2 and ORCA-3 clinical trials demonstrating statistically significant and clinically meaningful smoking cessation FDA acceptance starts the review process and sets timing for potentially the first new FDA-approved pharmacotherapy in two decades ...